gene and its prognostic significance in breast cancer. METHODS: To evaluate the diagnostic and prognostic significance of mesothelin, immunohistochemistry was used to assess the level of mesothelin protein in surgically resected, formalin-fixed, paraffin-embedded invasive breast carcinoma specimens. Associations between mesothelin and other biomarkers, including oestrogen receptor (OR), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2/neu), were also evaluated. RESULTS: A total of 182 breast carcinoma specimens were included.
Introduction
Breast cancer is one of the leading worldwide causes of cancer death among women. 1 Of particular interest is the fact that the incidence of breast cancer has increased sharply in China over the last two decades. 2 Clinical parameters, such as the size of the primary tumour, the histological grade and regional lymph node involvement are generally useful for prognosis. The profile of molecular markers may provide valuable insights into the underlying mechanisms of disease progression, thereby aiding intervention strategies. In light of the reported ethnic disparity in the incidence of breast cancer and disease prognosis, 3 it is important to identify and validate specific biomarkers for breast cancer in Chinese patients.
The mesothelin (MSLN) gene encodes a L Wang, Z Niu, L Zhang et al.
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69-kDa precursor protein that is processed to a 40-kDa membrane-bound protein, termed mesothelin, and a 31-kDa shed fragment called megakaryocytepotentiating factor. 4 Mesothelin is the antigen recognized by the monoclonal antibody K1, which was generated by immunization of BALB/c mice with the human ovarian carcinoma cell line OVCAR-3. 5 The biological function of mesothelin is unknown, although some studies have suggested that it might have a role in the spread of tumours. 6 It has been shown that expression of the MSLN gene is limited in normal tissues to the mesothelial cells lining the pleura, pericardium and peritoneum, 4, 5 and is high in several cancers, such as mesotheliomas, pancreatic and ovarian cancers. 7, 8 Overexpression of the MSLN gene in pancreatic adenocarcinoma has potential diagnostic, imaging and therapeutic implications. 7, 9 Expression of the MSLN gene in breast cancer has not been fully explored. Thus, the present study aimed to evaluate the prognostic value of measuring mesothelin protein levels in a large cohort of human breast cancer patients. Patients' tumour oestrogen receptor (OR) and progesterone receptor (PR) status, as well as HER2/neu protein status were assessed by immunohistochemical staining at the time of biopsy as part of routine hospital procedures. The breast cancer cell lines MCF-7 and T47D (American Type Culture Collection [ATCC], Rockville, MD, USA) were used as positive controls for OR and PR, respectively. The ovarian cancer cell line SK-OV-3 (ATCC) was used as a positive control for HER2/neu staining.
Patients and methods

STUDY POPULATION AND DIAGNOSIS
The present study was performed under a protocol approved by the Affiliated Hospital of Qingdao Medical College, Qingdao University, Qingdao and Tianjin Union Medicine Centre, Tianjin, China. All patients, or the families on behalf of deceased patients, provided written informed consent for inclusion of their data.
TREATMENT AND FOLLOW-UP
Patients without axillary lymph node involvement were treated by surgery alone, while patients with axillary lymph node involvement received six courses of adjuvant chemotherapy with a cyclophosphamide, methotrexate and fluorouracil regimen (dose and administration of the drugs was according to the body surface area). Patients with positive nodes or tumour size ≥ 5 cm received postoperative radiotherapy (2 Gy/day for 5 days/week for 5 weeks = 50 Gy total). Patients with OR-positive or PRpositive tumours were treated for 2 -5 years with tamoxifen (10 -20 mg twice a day). All patients, unless deceased, were followed for at least 36 months and up to 170 months. L Wang, Z Niu, L Zhang et al.
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The cases lost (due to death or other reasons) to follow-up were marked as censored data. The main study outcome was the number of months of postsurgical overall survival (OS).
IMMUNOHISTOCHEMICAL ANALYSIS FOR MESOTHELIN
The level of mesothelin protein in all tumour specimens was evaluated by immuno histochemical analysis. Briefly, 4-µm paraffinembedded sections were adhered to silanized slides, deparaffinized and hydrated by passing through xylene for 3 -5 min, then a graded series of ethanol (100%, 70% and 50% ethanol) for 5 min each and, finally, rinsing with distilled water for 10 min. Endogenous peroxidase activity was blocked using 3% hydrogen peroxide in methanol for 30 min between the first two ethanol stages.
After each of the following steps, sections were washed with 0.5 mol/l Tris-buffered saline (TBS; pH 7.6) for 5 min. Permeabilization of the sections was achieved, when required, by incubation with 0.05% trypsin for 30 min. Then, the tissue sections were covered with 2% normal rabbit serum in TBS for 20 min and the mesothelin monoclonal antibody clone 5B2 (1 : 20 dilution; Novocastra, Newcastle Upon Tyne, UK) was added for overnight incubation at 4°C. For each case, a corresponding section was incubated in TBS without the primary antibody as a control for nonspecific staining. The slides were then incubated with a biotinylated rabbit antimouse secondary antibody (1 : 50 dilution; Dako, Hamburg, Germany) for 40 min, followed by avidinbiotinylated peroxidase complex (0.01%; Dako) for an additional 40 min. After washing with distilled water for 10 min, staining was achieved using 3,3′diaminobenzidine. The sections were counterstained with Mayer's haematoxylin and eosin and mounted for microscopy.
SCORING OF MESOTHELIN IMMUNOREACTIVITY
Immunostained tissue sections were evaluated by two pathologists and mesothelin positivity was scored as the percentage of tumour cells that were positive for mesothelin. 7 The tissue specimens were categorized into three groups: mesothelin negative (-), < 1% of tumour cells stained positive for mesothelin; mesothelin positive (+), ≥ 1% to ≤ 25% of tumour cells stained positive; and mesothelin intensively positive (++), > 25% of tumour cells stained positive.
STATISTICAL ANALYSES
All statistical analyses were performed using SPSS ® statistical software, version 13.0 (SPSS Inc. Chicago, IL, USA) for Windows ® . Associations between mesothelin protein immunoreactivity score and clinicopathological variables were analysed using Pearson's χ 2 -analysis. OS and 95% confidence intervals were assessed by Kaplan-Meier survival analysis. Univariate and multivariate analyses of factors associated with OS were carried out using the Cox proportional hazards regression model. For the multivariate model, the cut-off Pvalue used to select the analysed factors from the univariate analysis was 0.10. Backward stepwise multivariate analysis was also used to find independent prognostic factors. A Pvalue < 0.05 was considered to be statistically significant.
Results
The patient cohort included a total of 182 cases of invasive breast cancer. The mean ± SD age was 49.7 ± 2.8 years; 86 patients were premenopausal and 96 were postmenopausal. Clinical stage assessed by TNM classification showed: tumour size < 2 cm in 31 cases, 2 -5 cm in 132 cases and > 5 cm in 19 cases; lymph node status N0 in 84 cases, L Wang, Z Niu, L Zhang et al.
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N1 in 32 cases, N2 in 46 cases and N3 in 20 cases; histological grade G1 in 52 cases, G2 in 47 cases and G3 in 83 cases. In total, 89 cases were OR positive and 93 were OR negative, 97 cases were PR positive and 85 were PR negative, and 36 cases were HER2/neu protein positive and 146 were HER2/neu protein negative.
Representative examples of the three different immunohistochemical staining levels for mesothelin protein (-, + and ++) in invasive breast cancer tissue are shown in Fig. 1 . Positive staining (≥ 1% of carcinoma cells) for mesothelin was seen in the cell membrane of carcinoma cells in 54 (29.7%) cases. Of the 54 mesothelin positive cases, 19 (35.2%) were scored as mesothelin intensively positive (i.e. ++ in > 25% of tumour cells), and 35 (64.8%) were mesothelin positive (i.e. + in ≥ 1% -≤ 25% of tumour cells). The percentage of cases with positive lymph node invasion was significantly higher in the mesothelin (+) and (++) groups compared with the mesothelin (-) group (P < 0.01). No significant difference was found between mesothelin (-), (+) and (++) cases in terms of histological grade, tumour size, PR, OR, HER2/neu levels and menopausal cases (data not shown).
The mean length of follow-up among the 182 patients was 92.7 months. Kaplan-Meier survival analyses showed a significant difference in OS between patients who were mesothelin (+) or (++) and patients who were mesothelin negative (P = 0.047; Table 1 ). When OS was stratified according to positive or negative lymph node status, mesothelin immunoreactivity was inversely associated with OS in the lymph node positive subgroups (P = 0.0428; Table 1 ), but not with the OS of the lymph node negative subgroups. In the Cox proportional hazards regression model, both univariate and multivariate analyses of OS showed that tumour size, lymph node positivity, HER2/neu positivity and mesothelin positivity were all indicators of poor OS (Table 2 ).
Discussion
Reaching an accurate prognosis of OS is one the most challenging issues in the management of breast cancer. The impact of racial, geographical and dietary factors on the incidence of breast cancer and survival have all been considered, however, at the histo - 
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pathological level, breast cancer is a highly heterogeneous disease and this hampers prognosis. Histological grading in the present study was not a reliable prognostic predictor of OS. The hormone receptors, OR and PR, and HER2/neu have been used as biomarkers with a certain degree of success. 10 -13 In the present study an association between the level of tumour mesothelin immunoreactivity and OS was demonstrated in patients with invasive breast cancer, raising the possibility that mesothelin may be used as a prognostic marker. To our knowledge, this is the first immunohistochemical study of the potential use of mesothelin as a biomarker for breast cancer among Chinese patients. L Wang, Z Niu, L Zhang et al.
The MSLN gene is highly expressed in several human cancers, including virtually all mesotheliomas and pancreatic adenocarcinomas, and approximately 70% of ovarian cancers, 50% of lung adenocarcinomas and 46% of oesophageal adenocarcinomas. 8,14 -17 The MSLN gene is also highly expressed in other adenocarcinomas of the biliary tree such as gallbladder cancer and tumours of the common bile duct. 7, 18 The significance of mesothelin protein levels in tumours in terms of clinical outcome in ovarian cancer studied by Yen et al. 19 Their study showed a correlation between tumour mesothelin protein levels, assessed by immunohistochemistry, and clinical outcome in 198 patients with ovarian serous carcinoma. Mesothelin immunoreactivity occurred in 55% of serous carcinomas with similar levels also observed in high-and lowgrade tumours. That study showed that, in patients with high-grade advanced-stage ovarian cancer treated with optimal debulking surgery and chemotherapy, diffuse tumour mesothelin immunostaining correlated significantly with prolonged survival. 19 Significant correlation between raised mesothelin level and poor survival has also been shown in gastric cancer and in aggressive malignant mesothelioma. 20, 21 The present study showed that mesothelin was present in the cell membrane of cancer cells and that higher levels of mesothelin correlated with temporal infiltration of the lymph nodes. The correlation between mesothelin level and poor OS and tumour infiltration of lymph nodes suggests that mesothelin may promote tumour invasion and could function as a potential predictive marker of OS in breast cancer.
The normal biological function of mesothelin is unclear. Bera et al. 18 developed mutant mice in which the Msln gene was inactivated and neither mesothelin mRNA nor protein were detected in the homozygous mutant mice. These Msln knockout mice did not have a detectable phenotype and both males and females produced offspring normally, suggesting that, in mice, mesothelin is not essential for growth or reproduction. Although the functions of mesothelin remain largely unknown, previous studies have shed light on the possible role of mesothelin in cancer biology. For example, mesothelinmucin 16 (MUC16) binding may be important in the peritoneal spread of ovarian cancer, so the inhibition of MUC16 binding to mesothelin could be a potentially useful strategy to treat ovarian cancer. 22 Prieve and Moon 23 showed that mesothelin was upregulated by Wnt1 through stable expression of the WNT1 gene in C57mg cells as well as by coculturing C57mg cells with Wnt1secreting cells. They also demonstrated that mesothelin was induced by lithium, an inhibitor of glycogen synthase kinase 3β that mimics Wnt1. 23 In contrast to Wnt1, Wnt5a downregulated mesothelin, perhaps through antagonism of the endogenous Wnt/β-catenin signalling pathway. 23 This suggests that mesothelin can be regulated by Wnt proteins. The two most widely accepted prognostic biomarkers for breast cancer are the hormone receptors, OR and PR, and the oncoprotein HER2/neu. The level of OR can be used to predict the response to endocrine therapy as well as to give a prognosis of OS. In contrast, HER2/neu positivity is predictive of a more aggressive tumour phenotype, poor diseasefree survival and poor OS. 24, 25 Currently, it is not known whether mesothelin is regulated by HER2/neu, although the present study did not find any significant relationship between mesothelin immunoreactivity and HER2/neu positivity, suggesting that mesothelin and HER2/neu are independent factors in breast cancer progression.
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